Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy

被引：67
|
作者：
Hwang, William L. [1 ,2 ]
Niemierko, Andrzej [2 ]
Hwang, Katie L. [2 ,3 ]
Hubbeling, Harper [3 ,4 ]
Schapira, Emily [2 ,3 ]
Gainor, Justin F. [4 ]
Keane, Florence K. [2 ]
机构：
[1] Harvard Med Sch, Harvard Radiat Oncol Program, Boston, MA USA
[2] Massachusetts Gen Hosp, Dept Radiat Oncol, 55 Fruit St, Boston, MA 02114 USA
[3] Harvard Med Sch, Boston, MA USA
[4] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA
来源：
JAMA ONCOLOGY | 2018年 / 4卷 / 02期
关键词：
PEMBROLIZUMAB; NIVOLUMAB; MELANOMA;
D O I：
10.1001/jamaoncol.2017.3808
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：253 / 255
页数：4
相关论文
共 50 条
  • [1] Herpes zoster in lung cancer patients treated with PD-1/PD-L1 inhibitors
    Taoka, Masataka
    Ochi, Nobuaki
    Yamane, Hiromichi
    Yamamoto, Takenobu
    Kawahara, Tatsuyuki
    Uji, Emiko
    Kosaka, Youko
    Takeda, Kouhei
    Nagasaki, Yasunari
    Nakanishi, Hidekazu
    Aoyama, Yumi
    Takigawa, Nagio
    [J]. TRANSLATIONAL CANCER RESEARCH, 2022, 11 (03) : 456 - 462
  • [2] Imaging evaluation of lung cancer treated with PD-1/PD-L1 inhibitors
    Mohammed, Nader
    Zhou, Rong Rong
    Xiong, Zeng
    [J]. BRITISH JOURNAL OF RADIOLOGY, 2021, 94 (1127):
  • [3] Clinical Outcomes in Metastatic Uveal Melanoma Treated With PD-1 and PD-L1 Antibodies
    Algazi, Alain P.
    Tsai, Katy K.
    Shoushtari, Alexander N.
    Munhoz, Rodrigo R.
    Eroglu, Zeynep
    Piulats, Josep M.
    Ott, Patrick A.
    Johnson, Douglas B.
    Hwang, Jimmy
    Daud, Adil I.
    Sosman, Jeffrey A.
    Carvajal, Richard D.
    Chmielowski, Bartosz
    Postow, Michael A.
    Weber, Jeffrey S.
    Sullivan, Ryan J.
    [J]. CANCER, 2016, 122 (21) : 3344 - 3353
  • [4] Immune-related adverse events (IRAEs) in metastatic lung cancer patients receiving PD-1/PD-L1 inhibitors and thoracic radiotherapy.
    Hwang, William L.
    Niemierko, Andrzej
    Willers, Henning
    Keane, Florence K.
    Gainor, Justin F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China
    Liu, Si-Yang
    Wu, Yi-Long
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10
  • [6] Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China
    Si-Yang Liu
    Yi-Long Wu
    [J]. Journal of Hematology & Oncology, 10
  • [7] Soluble PD-L1 levels correlate with efficacy of PD-1/PD-L1 inhibitors in lung cancer
    Kang, Da Hyun
    Koh, Jeong Suk
    Chung, Chaeuk
    Park, Dongil
    Lee, Song-I
    Lee, Jeong Eun
    [J]. RESPIROLOGY, 2023, 28 : 99 - 99
  • [8] Herpes zoster in patients with lung cancer treated with PD-1/PD-L1 antibodies
    Nagai, Yoshiaki
    Sata, Masafumi
    Ohta, Hiromitsu
    Onuki, Tsugitoshi
    Saito, Tatsuya
    Uchiyama, Ayumi
    Kurosaki, Ayako
    Yoshizumi, Naoko
    Takigami, Ayako
    Nakazawa, Shoko
    Nakayama, Masayuki
    Yamaguchi, Hironori
    Hagiwara, Koichi
    [J]. IMMUNOTHERAPY, 2022, 14 (15) : 1211 - 1217
  • [9] PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer
    Monneur, Audrey
    Goncalves, Anthony
    Bertucci, Francois
    [J]. BULLETIN DU CANCER, 2018, 105 (03) : 261 - 272
  • [10] Impact of the combined timing of PD-1/PD-L1 inhibitors and chemotherapy on the outcomes in patients with refractory lung cancer
    Yao, W.
    Zhao, X.
    Gong, Y.
    Zhang, M.
    Zhang, L.
    Wu, Q.
    Wu, L.
    Fan, Z.
    Yan, X.
    Jiao, S.
    [J]. ESMO OPEN, 2021, 6 (02)
12345